Max Rivera: Hey, I'll start with a kitchen instead of a number. Tuesday, 6:40 a.m., a mom, a nine-year-old with Turner syndrome, and the third missed growth hormone shot of the week.
Clara Bennett: Hold on. Third? Why so many?
Max Rivera: A sleepover, then a school trip. Nobody's failing here, it's just that a daily shot gives you seven chances a week to miss one. And on November 20th the FDA approved Sogroya, Novo Nordisk's once-weekly version, for Turner syndrome. First weekly one for it.
Clara Bennett: Remind listeners what Turner syndrome is before we go on.
Max Rivera: Right, a rare chromosomal condition in girls, with growth failure. Sorry, and the idea is simple. Pill organizer versus a once-a-week refill. The plan you'll keep beats the perfect plan you drop.
Clara Bennett: Mm. Slightly weaker but taken can beat stronger but skipped. What did the trial find?
Max Rivera: But that's the clean version, right? Slightly weaker. How much weaker? Because I keep wanting to ask if the girls on the weekly shot just ended up shorter.
Clara Bennett: It's called REAL8. Fifty-two weeks, 68 girls on weekly Sogroya, 37 on daily somatropin. Weekly grew 8.9 centimeters a year. Daily grew 9.7. The difference is minus 0.8, and the paper calls it nonsignificant.
Max Rivera: Nonsignificant. So, the same?
Clara Bennett: No. That's the trap. Nonsignificant mostly means the trial was too small to settle the question. Showing two drugs are equivalent is a different design, with a margin set in advance. Here the gap is just unresolved.
Max Rivera: Huh. So it's not "no difference." It's "we couldn't tell." And 37 girls on daily is, yeah, that's a small room to be certain in.
Clara Bennett: Now here's what surprised me. Point eight sounds tiny. But stack it over several years of treatment and it could reach several centimeters. Could. The trial only ran 52 weeks.
Max Rivera: Okay, but the kitchen. If she's missing two shots a week, that 9.7 isn't hers, is it? Trial families are motivated, they're monitored, somebody's checking the pens. Real-world daily is probably worse than 9.7, so, I mean, weekly might win at her counter.
Clara Bennett: Might. And the label now covers five pediatric indications for Sogroya, but the adherence advantage is assumed, not shown in this trial. So what evidence would show it? Real-world dosing records, tracked over years, with final height.
Max Rivera: So that's one bargain: a weaker number, but maybe a better real life. Same week, though, the FDA made a different bargain. November 17th, neladalkib, a lung cancer pill. What's it resting on?
Clara Bennett: First, a correction. Our notes said the 21st. Wrong. The FDA granted accelerated approval on November 17th, ten days before its November 27th target date. GSK holds it, and the brand is Nelkarmi.
Max Rivera: And the three approvals, Sogroya, this, and Sunharbor, that's a cluster? I kept wanting it to be a pattern.
Clara Bennett: It's a calendar coincidence. Sunharbor was approved for stroke prevention that week. Our sources give no trial, no mechanism. I'll say it exists and stop there.
Max Rivera: Fair. Okay, accelerated approval. Slow down. What is it?
Clara Bennett: Think of shipping a beta to users who have no other option. The pathway dates to 1992. The FDA approves on a surrogate endpoint, something reasonably likely to predict benefit. In return, the company owes confirmatory trials, and the approval can be withdrawn. Here the surrogate is response rate. Progression-free survival is the real test.
Max Rivera: Hmm, but a beta, yeah, in software a bug crashes your app. Here, a response means the tumor shrinks on a scan. That's not the same as living longer, right? So for someone who's progressed on alectinib, is this hope, or a coin flip?
Clara Bennett: Fair stress test. The trial is ALKOVE-1, single-arm, open-label, 222 patients. Confirmed response was 49%, 33 of 67, after alectinib. Then 32%, 50 of 155, in heavily pretreated patients. Those people had already failed other drugs. That's the case this pathway was built for. It also carries Breakthrough and orphan designations.
Max Rivera: Half responding still sounds low to me. But I guess the alternative for them is nothing. And the part that matters most, the why this drug exists, is what, resistance?
Clara Bennett: Hold that. Resistance mutations like G1202R, the brain, and GSK buying Nuvalent's science are the next piece, and they change how you read that 49%.
Max Rivera: But wait, the 49% isn't the whole story, is it? Picture a guy on alectinib. He gets a scan, and it shows growth. Yeah, so, he's been fine for a while, and now the tumor's back. Why?
Clara Bennett: Good question. You tell it. I think you've got the picture.
Max Rivera: Okay, so, the way I understand it, the tumor learns the lock. Alectinib is a key that fits the ALK protein. Some cells mutate, G1202R is one, and the key stops fitting. Those cells survive, they multiply, and, yeah, now you need a different key.
Clara Bennett: That's right. And it's why patients cycle through ALK drugs. Neladalkib is approved in two groups: after alectinib, or after two or more ALK inhibitors plus platinum chemotherapy. Nuvalent built it to fight those resistance mutations.
Max Rivera: Hm. So that's why 49% versus 32% matters. Earlier use works better?
Clara Bennett: Yes. The drug works best earlier, so sequencing matters. Dr. Alexander Drilon at Memorial Sloan Kettering, who led its development, said patients now have another option when other ALK inhibitors, including lorlatinib, have stopped working. He said it was designed to minimize neurological side effects and shrink cancer that has spread to the brain.
Max Rivera: The brain part. Wow. That's the detail that sticks for me. The tumor isn't only on a scan, it's in the place where side effects also hit.
Clara Bennett: Now add time. GSK's chief scientific officer, Tony Wood, said ALK-positive patients are often younger and can stay on treatment for years. So tolerability isn't a footnote.
Max Rivera: And GSK bought Nuvalent for this, right? Second lung cancer approval of 2026. I mean, it feels like collecting assets. Someone else did the science.
Clara Bennett: I'd put it differently. Acquisition is how most drugs reach global scale. Nuvalent developed it, and GSK can carry it everywhere.
Max Rivera: Fair. But then it's that same guy, a few years in, still taking the pill. Is that the real test?
Clara Bennett: It is the real test. Two bets, and both are waiting on data nobody has yet. For neladalkib, those response rates have to turn into longer progression-free survival in the confirmatory trial. For Sogroya, the weekly schedule has to show up as real adherence and real height. The FDA accepted a different kind of uncertainty in each case.
Max Rivera: Yeah, and it's funny, I started with that kitchen, the 6:40 a.m. one, thinking weekly was the obvious win. Now it's, I mean, it's a guess with a decent reason behind it. Same with the guy on alectinib. A 49% response is real, but he's really asking whether it buys him time, and nobody can tell him yet.
Clara Bennett: Right. And in both cases the question is whether anyone collects the follow-up and acts on it. Dosing records for the mom, final height years later. Confirmatory results for him.
Max Rivera: Mm. Somebody has to actually count the missed Tuesdays.
Clara Bennett: Someone does. Otherwise the pill organizer just sits on the counter, and nobody knows whether it helped.